Home » Insights » Insights Intercept Blood System
Cerus 12/05/2021

Beyond COVID-19: Plan now to future-proof* your therapeutic plasma 

As we’ve seen in the past, and now in the present, the continuity of the blood supply can be threatened by disease outbreaks. 

Cerus 21/12/2020

HemoMinas in Brazil adopts INTERCEPT for Platelets

Comércio Exportação e Importação de Materiais Médicos LTDA (CEI), a Cerus business partner, is awarded a three-year contract with the HemoMinas Foundation of Brazil for the INTERCEPTTM Blood System for platelets. 

Cerus 16/09/2020

Podcast: "Preparing our blood supply for the next pandemic" with Dr. Susan Stramer

Dr. Stramer discusses how pathogen outbreaks can impact blood safety and availability, and what to do about it. 

Cerus 28/05/2020

Inactivation efficacy of INTERCEPT for a broad spectrum of viruses and parasites

Despite the diligent implementation of strategies to minimize the risk of transfusion-transmitted infections, blood recipients, who are often vulnerable due to massive bleeding or immunosuppressive treatments are still at risk.

Cerus 22/04/2020

When you live in times when every platelet concentrate counts

With the outbreak of COVID-19 maintaining adequate inventory levels for platelet concentrates may be even more challenging than ever.

Cerus 27/02/2020

Pathogen inactivation of blood components during outbreaks of infectious diseases in the European Union

The European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organized an expert consultation meeting (April 2019) to discuss the potential role of pathogen inactivation technologies (PI) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not...